NCT02273544终止1 期
Bioavailability of Dipyridamole After Asasantin (Extended Release 200mg Dipyridamole/25mg ASA) in 3 Experimental Formulations (Given b.i.d. Over 3 or 5 Days, Respectively) Relative to the Standard Formulation in 16 Healthy Female and Male Subjects. Intraindividual Comparison, Randomised, Open
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 16
- 主要终点
- Urinary excretion of dipyridamole
研究概览
简要总结
The objective of this study was to compare the pharmacokinetics of dipyridamole in three different Asasantin ER batches (test) containing different amounts of retarding lacquers to the existing commercial product at steady state with b.i.d. treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female subjects as determined by results of screening
- •Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- •Female subjects are not lactating. Females must use adequate contraception (adequate contraception e.g. sterilization, IUP, oral contraceptives) prior to administration of study medication, during the study until after release from the study. Women must have negative blood pregnancy tests
- •Age >= 18 and <= 60 years
- •BMI >=18.5 and <=29.9 kg/m2 (see abbreviations for formula)
- •Able to communicate well with the investigator and to comply with study requirements
- •Laboratory values within a clinically defined reference range
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
- •Surgery of gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which were deemed relevant to the trial as judged by the investigator
- •Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
- •Use of any drugs, which might influence the results of the trial, (< 10 days prior to administration or during the trial)
- •Participation in another trial with an investigational drug (< 1 months prior to administration (at least 10 times the relevant elimination half-life) or during trial)
- •Having had prescription medication 2 weeks prior to study drug administration or over the counter medication 1 week prior to study drug administration (at least 10 times the relevant elimination half-life)
- •Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
- •Alcohol abuse (> 60 g/day)
- •Drug abuse
- •Use of methylxanthine-containing drinks or foods (coffee, tea, cola, energy drinks, chocolate, etc.), grapefruit or grapefruit juice, alcohol, green tea, or tobacco < 5 days prior to administration of study drug
- •Blood donation or loss > 400 mL (< 1 month prior to administration or during the trial)
- •Excessive physical activities (< 5 days prior to administration or during the trial)
- •Any ECG value outside of the reference range of clinical relevance including, but not limited to QTcB > 480 ms or QRS interval > 110 ms
- •History of any familial bleeding disorder
- •Inability to comply with dietary regimen of study centre
- •Inability to comply with investigator's instructions
- •For Female Subjects:
- •Pregnancy
- •Positive pregnancy test
- •No adequate contraception (adequate contraception e.g. sterilization, Intrauterine Pessary (IUP), oral contraceptives)
- •Inability to maintain this adequate contraception during the whole study period
- •Lactation period
- •During the interval between screening and start of drug administration tobacco and caffeine are restricted to avoid withdrawal when starting medication. As no relevant influence on Pharmacokinetic parameters is known moderate tobacco and caffeine consumption are allowed to facilitate trial participation (up to 10 cigarettes or 3 cigars or 3 pipes/day, and/or up to three cups of coffee respectively). Ovarian hormone substitution and oral contraception are allowed to be continued during the study
研究组 & 干预措施
Asasantin ER - commercial formulation
Active Comparator
干预措施: Asasantin ER - commercial formulation (Drug)
Asasantin ER (new formulation - low)
Experimental
干预措施: Asasantin ER (new formulation - low) (Drug)
Asasantin ER (new formulation- high)
Experimental
干预措施: Asasantin ER (new formulation - high) (Drug)
Asasantin ER (new formulation - medium)
Experimental
干预措施: Asasantin ER (new formulation - medium) (Drug)
结局指标
主要结局
Urinary excretion of dipyridamole
时间窗: day 2, day 3
geometric means of percentage of amount excreted from time zero to 10 h (% Ae 0-10h)
次要结局
- Number of subjects with adverse events(up to 1 month)
- Cmax urine (Maximum measured concentration of the analyte)(0 to 3 hours after drug intake)
- Cmin (Minimum measured concentration of the analyte)(8 - 10 hours after drug intake)
- % PTF urine (peak trough fluctuation)(Up to 10 hours after drug intake)
研究者
相似试验
已完成
1 期
Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male SubjectsHealthyNCT02273557Boehringer Ingelheim19
已完成
1 期
Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female VolunteersHealthyNCT02273518Boehringer Ingelheim18
已完成
1 期
Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy SubjectsHealthyNCT02273505Boehringer Ingelheim20
进行中（未招募）
1 期
The effect of dipyridamole on the pharmacokinetics of metformin.MedDRA version: 14.1Level: PTClassification code 10068071Term: Inhibitory drug interactionSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 14.1Level: PTClassification code 10013710Term: Drug interactionSystem Organ Class: 10018065 - General disorders and administration site conditionsThe antihyperglycemic drug metformin and the thrombocyte aggregation inhibitor dipyridamole are often used concomitantly in patients with diabetes who have suffered a transient ischemic attack or stroke. Gastrointestinal absorption of metformin is mediated by the equilibrative nucleoside transporter 4 (hENT4). Dipyridamole has been reported to inhibit hENT4 transport in vitro. Dipyridamole may therefore negatively influence the uptake of metformin from the gastrointestinal tract.EUCTR2012-000363-24-NLRadboud University Medical Centre Nijmegen18
招募中
4 期
The effect of dipyridamole on the pharmacokinetics of metformin.geneesmiddeleninteractieDrug interactionNL-OMON37582niversitair Medisch Centrum Sint Radboud18